Want to see HK:2269 full AI Analyst Report?
Top Page
Wuxi Biologics (Cayman)
(2269)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$55.00
▲(8.59% Upside)
Action:Upgraded
Date:08/06/26
The score is driven primarily by strong financial quality (healthy margins and low leverage) and supportive technical momentum (price above key moving averages with positive MACD). These positives are moderated by slowing recent revenue growth, weaker cash conversion versus earnings, and a mid-to-high P/E with no dividend yield data.
Positive Factors
Healthy profitability
Strong 2025 gross, EBIT, and net margins show that the CDMO model is currently generating meaningful profit from its service platform. This profitability provides internal resources for research, capacity, and operational investment while supporting resilience across development and manufacturing activities.
Negative Factors
Recent growth deceleration
The sharp slowdown in annual revenue growth indicates that prior expansion has not recently translated into the same pace of top-line progress. If sustained, slower project or customer growth could reduce operating leverage and limit the rate at which the company expands its biologics platform.
Read all positive and negative factors
Positive Factors
Negative Factors
Healthy profitability
Strong 2025 gross, EBIT, and net margins show that the CDMO model is currently generating meaningful profit from its service platform. This profitability provides internal resources for research, capacity, and operational investment while supporting resilience across development and manufacturing activities.
Read all positive factors
Wuxi Biologics (Cayman) (2269) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$204.24B
Dividend YieldN/A
Average Volume (3M)41.10M
Price to Earnings (P/E)34.8
Beta (1Y)1.70
Revenue Growth21.93%
EPS Growth21.94%
CountryHK
Employees14,705
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.21
Shares Outstanding4,152,929,700
10 Day Avg. Volume46,532,898
30 Day Avg. Volume41,099,456
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)2.49
Price to Sales (P/S)5.41
P/FCF Ratio42.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$57.58Price Target Upside13.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)1.4
Revenue Forecast (FY)HK$25.66B
Wuxi Biologics (Cayman) Business Overview & Revenue Model
Company Description
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufactu...
How the Company Makes Money
Wuxi Biologics makes money primarily by selling fee-based, outsourced R&D and manufacturing services to biopharmaceutical customers developing biologic medicines. Its revenue model is project- and contract-driven across the biologics value chain: ...
Wuxi Biologics (Cayman) Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.62B | 21.79B | 18.68B | 17.03B | 15.27B | 10.29B |
| Gross Profit | 11.21B | 10.02B | 7.65B | 6.83B | 6.72B | 4.83B |
| EBITDA | 8.84B | 7.92B | 6.43B | 5.50B | 6.22B | 4.51B |
| Net Income | 5.01B | 4.91B | 3.36B | 3.40B | 4.42B | 3.39B |
Balance Sheet | ||||||
| Total Assets | 65.35B | 63.72B | 56.98B | 56.58B | 49.56B | 44.03B |
| Cash, Cash Equivalents and Short-Term Investments | 13.04B | 15.74B | 10.71B | 11.24B | 8.71B | 11.13B |
| Total Debt | 2.73B | 3.11B | 4.94B | 4.56B | 4.42B | 4.30B |
| Total Liabilities | 10.80B | 10.66B | 11.50B | 12.56B | 13.35B | 11.33B |
| Stockholders Equity | 48.06B | 47.27B | 41.82B | 40.33B | 35.05B | 32.28B |
Cash Flow | ||||||
| Free Cash Flow | 2.79B | 2.80B | 1.29B | 437.20M | -326.72M | -3.09B |
| Operating Cash Flow | 4.60B | 6.39B | 5.22B | 4.67B | 5.54B | 3.43B |
| Investing Cash Flow | -2.70B | -3.38B | -3.94B | -3.23B | -5.91B | -9.60B |
| Financing Cash Flow | -1.01B | -1.95B | -2.75B | 1.96B | -2.59B | 8.21B |
Wuxi Biologics (Cayman) Technical Analysis
Positive
50.65
Price Trends
42.39
Positive
37.74
Positive
36.53
Positive
Market Momentum
2.31
Positive
58.16
Neutral
28.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2269, the sentiment is Positive. The current price of 50.65 is above the 20-day moving average (MA) of 48.60, above the 50-day MA of 42.39, and above the 200-day MA of 36.53, indicating a bullish trend. The MACD of 2.31 indicates Positive momentum. The RSI at 58.16 is Neutral, neither overbought nor oversold. The STOCH value of 28.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2269.
Wuxi Biologics (Cayman) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$204.24B | 34.80 | 10.51% | ― | 21.93% | 21.94% | |
66 Neutral | HK$26.93B | 61.04 | 15.79% | ― | 48.04% | 166.72% | |
62 Neutral | HK$68.87B | -13.44 | -16.23% | 0.35% | 53.48% | -120.02% | |
60 Neutral | HK$2.78B | 13.92 | 4.45% | 0.27% | 7.38% | 7.90% | |
59 Neutral | HK$80.18B | 42.46 | 10.96% | 0.82% | 20.39% | 26.48% | |
58 Neutral | HK$2.64B | 31.76 | 3.02% | ― | 10.32% | 178.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2269
Wuxi Biologics (Cayman)
48.48
9.50
24.37%
HK:1548
Genscript Biotech
31.00
12.92
71.46%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
28.20
4.31
18.04%
HK:1521
Frontage Holdings Corp.
1.20
-0.13
-9.77%
HK:1873
Viva Biotech Holdings
1.33
-1.47
-52.68%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
58.00
32.16
124.46%
Wuxi Biologics (Cayman) Corporate Events
WuXi Biologics Schedules Conference Calls to Present 2026 Interim Results
Aug 25, 2026
WuXi Biologics (Cayman) Inc., a Hong Kong-listed provider of contract biologics research and manufacturing services, offers end-to-end solutions to pharmaceutical and biotech clients worldwide. The company operates within the life sciences sector,...
Wuxi Biologics Posts Strong Interim Growth as Integrated Biologics Project Portfolio Expands
Aug 25, 2026
Wuxi Biologics reported unaudited interim results for the six months ended June 30, 2026, showing revenue rising 18.4% year-on-year to RMB 11,787.2 million and gross profit up 28.1%. Net profit grew 5.8% to RMB 2,916.2 million, while adjusted net ...
WuXi Biologics sets August board meeting to approve interim 2026 results
Jul 24, 2026
WuXi Biologics (Cayman) Inc. has scheduled a board meeting in Hong Kong on August 25, 2026 to consider and approve the group’s interim results for the six months ended June 30, 2026. The forthcoming review and publication of these interim fi...
WuXi Biologics Wins Full Shareholder Backing at 2026 AGM
Jun 10, 2026
WuXi Biologics said shareholders approved all resolutions at its 10 June 2026 annual general meeting, including the 2025 audited financial statements and the re-election of three directors, with most items passing with overwhelming majorities. Inv...
Wuxi Biologics Grants Time-Based Restricted Shares to 21 Employees
Jun 9, 2026
Wuxi Biologics has approved the grant of 288,441 restricted shares at no purchase cost to 21 employees under its Restricted Share Award Scheme, with a market reference price of HK$29.94 per share on the grant date. The award vests in four equal an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.